The Association for Accessible Medicines recently released its 2023 U.S. Generic & Biosimilar Medicines Saving Report, highlighting the value of generic and biosimilar medicines. The report noted that the U.S. healthcare system—including patients, employers and taxpayers—saved $408 billion in 2022 by using FDA-approved generic and biosimilar drugs.
At the same time, AAM pointed out that “it is critical not to take these savings for granted, as growing challenges to a sustainable future for generic and biosimilar competition continue to rise.”
Indeed, the generics industry faces myriad challenges, including the need to ensure a consistent supply of critical products, pressure on margins, deflation and port staffing issues, while also developing and launching new products.
To understand what the generics industry is facing and how it plans to catapult ahead, Drug Store News called up executives from leading generics firms to share their views on the state of the generics industry. Their answers shed light on the tenaciousness of the industry and its ability to go the extra mile to serve their customers and patients.
DSN: How do you plan to help customers and patients in 2024?
Boyer: Where profitable, Amneal plans to continue delivering high-demand and high-impact products, like lisdexamfetamine dimesylate, calcium gluconate injection and naloxone nasal spray, to the market, offering customers consistent supply from the quality-focused and reliable partner we are.
Dillaway: Ascend takes some extra steps in assisting patients directly. We receive a high number of calls from patients who are specifically looking for the Ascend product. Many say their pharmacy made a change and now provides them a different manufacturer whose product may cause an unwanted side effect or in their estimation is less effective. For these customers, Ascend has partnered with PursueCare, a mail order pharmacy in W.Va., that has agreed to carry all Ascend products and take these patients as referrals in order to fill their requests for the Ascend brand. Patients are put in touch with PursueCare who can quickly transfer their prescription and deliver the desired product to them.
Ascend’s chief medical officer is an actual practicing primary care physician who is available to help with patient questions.
McMahon: In fiscal year 2023, Aurobindo led the market in ANDA approvals and filed 49 Abbreviated New Drug Applications and received final approval for 59 ANDAs. In addition, the company successfully launched and relaunched 24 products. Aurobindo Pharma looks forward to launching many more products in the coming months, as the company continues to expand its portfolio with nearly 200 pending approvals. This brings us to over 700 FDA-approved Abbreviated New Drug Applications to date. Aurobindo remains focused on strengthening our existing businesses and developing a differentiated and specialty-
driven product portfolio.
In addition to our robust organic pipeline, the organization recently acquired another manufacturing facility. Aurobindo continues to invest in infrastructure in terms of plant and capacity expansions and building new facilities, all of which will fuel our growth. We are pleased to announce our new Luoxin facility, located in China, where we’ll be producing the blow-fill-seal inhalation products, the first of which will be levalbuterol, followed by albuterol, ipratropium and others, beginning early 2024.
To keep up with demand and continue to set itself apart, it is critical for Aurobindo to have highly competitive costs and product availability while holding to the best-in-class standards of compliance and quality. By doing so, the company is continuing to grow in a sustainable manner and successfully delivering billions of doses of medicine every month to its customers and patients. We are thrilled to announce we are offering copay cards to patients for four of our specialty products: vigabatrin tablets, ambrisentan tablets, pyrimethamine tablets and lenalidomide capsules.
Kikuchi: The best way to help patients and customers is to better understand their needs. Communication is a key. Dr. Reddy’s communicates and connects at all levels, from top executives to multi-level executives below. We believe it’s essential to make connections at all levels to provide the best service and get the most comprehensive feedback from our customers. We’re able to get the best input from connecting with various level executives to understand where there’s a real need. We have several tiers of staff that interact with customers as well as both OTC and specialty sales teams, all of whom interact daily as well as in more formalized weekly and monthly meetings. There’s constant communication, based on an incredible dedication to meeting patients’ unmet needs.
Then we must act on those unmet needs. This means maintaining a strong pipeline to facilitate the launch of new products. A continuous stream of new product launches will provide customers and patients with more affordable options and enhance access to products and services that they need. We will continue to be guided by our deep-rooted philosophy that Good Health Can’t Wait. As a leader in the pharmaceutical industry, we have the ethical and moral imperative to accelerate access to much-needed medicines for people around the world. Our philosophy of Good Health Can’t Wait is guidance for our current behavior and inspiration for our future actions.